Akari Therapeutics is a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its innovative ADC discovery platform, the Company has the ability to generate novel bi-functional ADC candidates and optimize them based on the desired application to target a range of cancers to fuel a growing pipeline. Akari’s lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells and with a proprietary linker delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their toxin classes, PH1 is a novel bi-functional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Given this mechanism, AKTX-101 has the potential to overcome many of the shortcomings of current ADCs, off-target toxicity and resistance. In preclinical studies, AKTX-101 has shown to have superior activity, prolonged survival, less resistance and better tolerability and safety. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival in preclinical models. The Company is generating validating data on its novel payloads to advance its pipeline.
Company Details
- Employees
- 13
- Address
- 75-76 Wimpole Street, London,w1g 9rt,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.akaritx.com
- Keywords
- Representative jobs.
- HQ
- London
Akari Therapeutics, Plc Questions
Akari Therapeutics, Plc's website is http://www.akaritx.com
Akari Therapeutics, Plc's LinkedIn profile is https://www.linkedin.com/company/akaritx
Akari Therapeutics, Plc has
13 employees.
View email and phone details for 13
employees at Akari Therapeutics, Plc.
Akari Therapeutics, Plc's industry is
Biotechnology Research
Akari Therapeutics, Plc's top competitors are
Lentitek,
Biocomposites,
Callio Therapeutics,
Longeveron,
Nuvation Bio,
Bioxcel Therapeutics, Inc.,
Eikon Therapeutics,
Garuda Therapeutics,
Tenaya Therapeutics,
Peak Bio Inc..
Akari Therapeutics, Plc's categories are Biotechnology Research
